Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions
Top Cited Papers
- 6 June 2019
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 380 (23), 2225-2236
- https://doi.org/10.1056/nejmoa1815281
Abstract
The BCL2 inhibitor venetoclax has shown activity in patients with chronic lymphocytic leukemia (CLL), but its efficacy in combination with other agents in patients with CLL and coexisting conditions is not known.This publication has 28 references indexed in Scilit:
- Traditional multiplicity adjustment methods in clinical trialsStatistics in Medicine, 2013
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing plateletsNature Medicine, 2013
- Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLLLeukemia, 2012
- The Tumor Lysis SyndromeNew England Journal of Medicine, 2011
- A Manual of Guidelines to Score the Modified Cumulative Illness Rating Scale and Its Validation in Acute Hospitalized Elderly PatientsJournal of the American Geriatrics Society, 2008
- Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelinesBlood, 2008
- The changing prevalence of comorbidity across the age spectrumCritical Reviews in Oncology/Hematology, 2008
- International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemiaLeukemia, 2007
- Genomic Aberrations and Survival in Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 2000
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976